Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma

Anti-Cancer Drugs

Volumn 15, Issue 6, 2004, Pages 641-646

  Yuan, Shengtao ^a   Zhang, Xiongwen ^a   Lu, Lijuan ^a   Xu, Chenghui ^a   Yang, Weiyi ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Anticancer activity; Doxorubicin; Hepatocellular carcinoma; in vitro; in vivo; Methoxymorpholinyl doxorubicin; PNU 152243

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MITOMYCIN; NEMORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ACUTE TOXICITY TESTS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3142695380     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000132238.23050.f5     Document Type: Article

References (31)

1. Blum RH, Carter SK. A new anticancer drug with significant clinical activity. Ann Intern Med 1974; 80:249-259.
2. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC, et al. Early anthracycline cardiotoxicity. Am J Med 1978; 65:823-832.
3. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316:1388-1393.
4. Sikic BI, Ehsan MN, Harker WG, Friend NF, Brown BW, Newman RA, et al. Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. Science 1985; 228:1544-1546.
5. Danesi R, Agen C, Grandi M, Nardini V, Bevilacqua G, Del Tacca M. 3′-Deamino-3′-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. Eur J Cancer 1993; 29A:1560-1565.
6. Streeter DG, Taylor DL, Acton EM, Peters JH. Comparative cytotoxicities of various morpholinyl anthracyclines. Cancer Chemother Pharmacol 1985; 14:160-164.
7. Watanabe M, Komeshima N, Nakajima S, Tsuruo T. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Cancer Res 1988; 48:6653-6657.
8. Geroni C, Pesenti E, Broggini M, Belvedere G, Tagliabue G, D'Incalci M, et al. L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives. Br J Cancer 1994; 69:315-319.
9. Grandi M, Pezzoni G, Ballinari D, Capolongo L, Suarato A, Bargiotti A, et al. Novel anthracycline analogs. Cancer Treat Rev 1990; 17:133-138.
10. Bakker M, Renes J, Groenhuijzen A, Visser P, Timmer-Bosscha H, Muller M, et al. Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines. Int J Cancer 1997; 73:362-366.
11. Ripamonti M, Pezzoni G, Pesenti E, Pastori A, Farao M, Bargiotti A, et al. In vivo anti-tumor activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistance tumor cells. Br J Cancer 1992; 65:703-707.
12. Chen R, Zhu D, Ye X, Shen D, Lu R. Establishment of three human liver carcinoma cell lines and some of their biological characteristics in vitro. Sci Sin 1980; 23:236-247.
13. Lu J, Xu RB, Doung RC. The glucocorticoid receptors and the induction of tyrosine aminotransferase by glucocorticoid in the human liver cancer cell line (SMMC-7721) in vitro. Shih Ken Sheng Wu Hsueh Pao 1985; 18:231-238.
14. Zannis VI, Breslow JL, SanGiacomo TR, Aden DR Knowles BB. Characterization of the major apolipoproteins secreted by two human hepatoma cell lines. Biochemistry 1981; 20:7089-7096.
15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
16. Eustice DC, Brittelli DR, Feldman PA, Brown LJ, Borkowski JJ, Slee AM. An automated pulse labelling method for structure-activity relationship studies with antibacterial oxazolidinones. Drugs Exp Clin Res 1990; 16:149-155.
17. 50) and its error with a small computer. J Toxicol Environ Health 1977; 3:797-809.
18. Wand WR. In vivo methods. In: Teicher BA (editor): Anticancer Drug Development Guide, Preclinical Screening, Clinical Trials and Approval. Totowa, NJ: Humana Press; 1997, pp. 59-213.
19. Stewart BW, Kleihues P. Liver cancer. In: Stewart BW, Kleihues P (editors): World Cancer Report. Lyon: IARC Press; 2003, pp. 203-207.
20. Itsubo M. The present status of chemotherapy for HCC. Jpn J Cancer Chemother 1993; 20:889-895.
21. Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma: experience with 109 patients. Cancer 1985; 56:2751-2755.
22. 2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984; 68:487-491.
23. Ihde DC, Kane RC, Cohen MH, McIntire KR, Minna JD. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 1977; 61:1385-1387.
24. Bing-hui Y, Zhao-you T. Randomized clinical trial of cisplatin in the treatment of hepatocellular carcinoma. In: Zhao-you T, Meng-chao W, Sui-sheng X (editors): Primary Liver Cancer. New York: Springer; 1989, pp. 434-437.
25. Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP. Chemotherapy studied in primary liver cancer: a prospective randomized trial. Cancer 1978; 42:2149-2156.
26. Vasey PA, Bissett D, Strolin-Benedetti M, Poggesi I, Breda M, Adams L, et al. Phase I clinical and pharmacokinetic study of 3′-deamino-3′-(2- methoxy-4-morpholinyl)-doxorubicin (FCE 23762). Cancer Res 1995; 55:2090-2096.
27. Sessa C, Zucchetti M, Ghielmini M, Bauer J, D'Incalci M, de Jong J, et al. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). Cancer Chemother Pharmacol 1999; 44:403-410.
28. Fokkema E, Verweij J, van Oosteram AT, Uges DR, Spinelli R, Valota O, et al. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study. Br J Cancer 2000; 82:767-771.
29. Bakker M, Droz JP, Hanauske AR, Verweij J, van Oosterom AT, Groen HJ, et al. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. Br J Cancer 1998; 77:139-146.
30. Lau DH, Duran GE, Lewis AD, Sikic BI. Metabolic conversion of methoxymorpholinyl doxorubicin: form a DNA strand breaker to a DNA cross-linker. Br J Cancer 1994; 70:79-84.
31. Quintieri L, Rosato A, Napoli E, Sola F, Geroni C, Floreani M, et al. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A. Cancer Res 2000; 60:3232-3238.